Brief: Poxel Announces Positive Results From Phase 2 NASH Trial For PXL065

Poxel SA

30/08/2022 09:52

Aug 30 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL ANNOUNCES POSITIVE RESULTS FROM PHASE 2 NASH TRIAL
(DESTINY-1) FOR PXL065, A NOVEL, PROPRIETARY
DEUTERIUM-STABILIZED R-STEREOISOMER OF PIOGLITAZONE
    * KEY SECONDARY MEASURES IN PXL065-TREATED PATIENTS INCLUDED
A
STATISTICALLY SIGNIFICANT IMPROVEMENT IN PRO-C3, A BIOMARKER OF
FIBROGENESIS
    * HISTOLOGY RESULTS PENDING IN SEPTEMBER, ALONG WITH
POSITIVE
INITIAL READOUT, WILL INFORM NEXT STEPS OF PXL065 IN NASH,
INCLUDING POTENTIAL FOR PHASE 3 DEVELOPMENT
    * ADDITIONAL DATA FROM HISTOLOGY RESULTS ARE EXPECTED IN
SEPTEMBER
    * FULL PHASE 2 RESULTS WILL BE SUBMITTED FOR PRESENTATION AT
AN
UPCOMING SCIENTIFIC MEETING.
    * PXL065 WAS OBSERVED TO BE SAFE AND WELL TOLERATED WITH NO
DOSE
DEPENDENT INCREASE IN BODY WEIGHT AND NO INCREASED LOWER
EXTREMITY EDEMA VERSUS. PLACEBO
    * SAFETY PROFILE IS CONSISTENT WITH REDUCED PPARG-MEDIATED
SIDE
EFFECTS VERSUS. PUBLISHED RESULTS OF PIOGLITAZONE
    * PHASE 2 TRIAL FOR TREATMENT OF NASH MET ITS PRIMARY
EFFICACY
ENDPOINT

Source text for Eikon:  ID:nBw6r70l6a 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))